Newer influenza antivirals, biotherapeutics and combinations.
about
Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza virusesPreliminary success in the characterization and management of a sudden breakout of a novel H7N9 influenza A virus.Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro.Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical managementFlipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.Advances in antivirals for non-influenza respiratory virus infections.Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interactionPreclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.NADPH Oxidase 1 Is Associated with Altered Host Survival and T Cell Phenotypes after Influenza A Virus Infection in MiceOX40 ligand newly expressed on bronchiolar progenitors mediates influenza infection and further exacerbates pneumonia.Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication.Quantifying the therapeutic requirements and potential for combination therapy to prevent bacterial coinfection during influenza.Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.Identification of Polo-like kinases as potential novel drug targets for influenza A virus.Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.Anti-inflammatory effects of indirubin derivatives on influenza A virus-infected human pulmonary microvascular endothelial cells.Mechanisms of action and efficacy of statins against influenza.Novel antiviral agents for respiratory viral infection in immunocompromised adults.Therapy of H7N9 pneumonia: current perspectives.Host-pathogen kinetics during influenza infection and coinfection: insights from predictive modeling
P2860
Q28541953-3F2DB732-F531-4212-AEAA-BE274BC1792BQ30358886-7823E7B9-E330-491D-9D34-672CFD823951Q30361598-4953DE20-7BE2-49A6-9B81-53745F30CF49Q30368680-DB044BE0-82E1-42B6-A5D0-0D2A0F5BFCE3Q30369353-81B85FE7-589E-495B-A86D-4B0CABD63CB4Q30377702-D4C291B1-11F1-4DC5-8373-218539FD6DA7Q30457132-812502C7-29FD-4A23-B2B1-AA43CDE74BC7Q33638356-44F464A7-5152-4F33-877F-AF35B1F803A5Q35076802-2726971E-D6C7-426B-9A2F-CB5E77A9ECDDQ35127236-E798B390-8B34-4CA7-BC60-1411ED86275DQ35934016-62B566FE-D046-42FF-A253-D400990A4813Q36759480-BA95CC24-3475-48CF-8757-4092FD4AB03EQ37346000-44BC52A0-5AFA-4403-B00D-0AA54F279F1EQ37733491-D34FC861-598F-4E96-A21D-703C38C63CC8Q39152320-C28F4E25-E367-4562-829E-22554ACBEA59Q40058871-2E0EC7D3-1550-4551-95F7-ACCCE0405D69Q40078929-8FACDE78-D181-4A01-833A-8FE9D44C6F7DQ40622883-93939087-FE52-4714-BA66-7087B60C92FFQ40844952-4E0DF2EE-FBA8-4720-BB07-3BD2B21EFAF2Q42177559-AD2D227C-76F0-465D-9674-E63D20BA6F98Q42243405-D0109524-6456-4998-BD65-A03FAAFCBBA5Q51861450-D972943A-C3B7-44F4-9220-B31B3A933DEBQ57232542-46A892DA-90FE-4461-80A2-CC2028526755
P2860
Newer influenza antivirals, biotherapeutics and combinations.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Newer influenza antivirals, biotherapeutics and combinations.
@ast
Newer influenza antivirals, biotherapeutics and combinations.
@en
type
label
Newer influenza antivirals, biotherapeutics and combinations.
@ast
Newer influenza antivirals, biotherapeutics and combinations.
@en
prefLabel
Newer influenza antivirals, biotherapeutics and combinations.
@ast
Newer influenza antivirals, biotherapeutics and combinations.
@en
P2860
P921
P356
P1476
Newer influenza antivirals, biotherapeutics and combinations.
@en
P2860
P356
10.1111/IRV.12045
P478
P577
2013-01-01T00:00:00Z